NCT06581406 2026-02-18
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Replimune Inc.
Phase 2/3 Recruiting
Clinical Trials
4 trialsNCT06947928 2025-10-14
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, Inc.
Phase 2/3 Recruiting
NCT01861938 2025-10-02
Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
Hadassah Medical Organization
Phase 2/3 Withdrawn
NCT00055562 2005-06-24
Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma
Celgene
Phase 2/3 Completed